Génotypage moléculaire dans les cancers réfractaires de la thyroïde en 2021 : quand, comment, et pourquoi ? Un travail du réseau TUTHYREF
Open Access
- 1 November 2021
- journal article
- review article
- Published by Elsevier in Bulletin du Cancer
- Vol. 108 (11) , 1044-1056
Abstract
No abstract availableKeywords
This publication has 90 references indexed in Scilit:
- Identification of kinase fusion oncogenes in post-Chernobyl radiation-induced thyroid cancersJournal of Clinical Investigation, 2013
- Cabozantinib in Progressive Medullary Thyroid CancerJournal of Clinical Oncology, 2013
- Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid CancerNew England Journal of Medicine, 2013
- SomaticRASMutations Occur in a Large Proportion of SporadicRET-Negative Medullary Thyroid Carcinomas and Extend to a Previously Unidentified ExonThe Journal of Clinical Endocrinology & Metabolism, 2012
- Activation of the mTOR Pathway in Primary Medullary Thyroid Carcinoma and Lymph Node MetastasesClinical Cancer Research, 2012
- Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III TrialJournal of Clinical Oncology, 2012
- Results of combined treatment of anaplastic thyroid carcinoma (ATC)BMC Cancer, 2011
- Poorly Differentiated Thyroid Carcinoma: The Turin Proposal for the Use of Uniform Diagnostic Criteria and an Algorithmic Diagnostic ApproachAmerican Journal of Surgical Pathology, 2007
- Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosisCancer, 2006
- Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2004